EJC Skin Cancer最新文献

英文中文

Pediatric Spitz Melanoma: a case report 小儿斯皮兹黑色素瘤：1例报告

EJC Skin Cancer

Pub Date : 2025-01-01 DOI: 10.1016/j.ejcskn.2025.100374

S. Martinez, K. Karanfilian, O.P. Sangueza

引用次数: 0

Clinical and histopathological characteristics and prognosis of 6790 patients with malignant melanoma in Japan 6790例日本恶性黑色素瘤患者的临床、组织病理学特征及预后分析

EJC Skin Cancer

Pub Date : 2025-01-01 DOI: 10.1016/j.ejcskn.2025.100353

K. Nishihara , Y. Fujisawa , H. Iwata , T. Fujimura , H. Uhara , T. Hoashi , T. Takenouchi , J. Asai , S. Yoshikawa , K. Namikawa , T. Maeda , T. Miyagawa , Y. Sawada , H. Kawahira , F. Ohno , Y. Nakamura , T. Fukumoto , Y. Nakamura , S. Sugihara , Y. Shibayama , S. Mori

引用次数: 0

Clinicopathologic and gene expression profile (CP-GEP) is a biomarker for outcome in patients with melanoma eligible for sentinel lymph node biopsy (SLNB) 临床病理和基因表达谱（CP-GEP）是符合前哨淋巴结活检（SLNB）条件的黑色素瘤患者预后的生物标志物。

EJC Skin Cancer

Pub Date : 2025-01-01 DOI: 10.1016/j.ejcskn.2025.100378

L. Zijlker , Z. Verwer , A. Kuijpers , M. Wouters , W. van Houdt , A. van Akkooi

引用次数: 0

A pilot study evaluating the 3D morphology of melanocytic lesions with LC-OCT and correlating findings to histopathology and RCM 一项初步研究评估黑素细胞病变的LC-OCT三维形态以及与组织病理学和RCM相关的发现

EJC Skin Cancer

Pub Date : 2025-01-01 DOI: 10.1016/j.ejcskn.2025.100381

M.J. Pérez-Anker , S. Puig , L. Alos , A. Garcia , B. Alejo , E. Cinotti , C. Orte Cano , L. Tognetti , C. Lenoir , P. Castillo , P. Rubegni , M. Suppa , J.L. Perrot , V. Del Marmol , J. Malvehy

引用次数: 0

Corrigendum to “The “Lone Wolf” sign: An underutilised aid for the diagnosis of melanoma in patients lacking multiple nevi” [EJC Skin Cancer 2 (2024) 100268] “独狼”标志的勘误表：缺乏多重痣的患者诊断黑色素瘤的未充分利用的辅助工具”[EJC皮肤癌2 (2024)100268]

EJC Skin Cancer

Pub Date : 2025-01-01 DOI: 10.1016/j.ejcskn.2025.100744

Jacques Pierre du Toit, Johann de Wet

引用次数: 0

Patterns of systemic treatment for melanoma: An insight on trends and costs between 2019–2023 from the English systemic anti-cancer therapy national database 黑色素瘤的全身治疗模式：来自英国全身抗癌治疗国家数据库的2019-2023年趋势和成本洞察

EJC Skin Cancer

Pub Date : 2025-01-01 DOI: 10.1016/j.ejcskn.2024.100279

Tommaso Bosetti , Oliver John Kennedy , Rebecca Lee , Avinash Gupta , Patricio Serra , Nadia Ali , Avanti Andhale , Sophia Kreft , Paul Lorigan

Introduction

Checkpoint inhibitors (CPI) and targeted therapy (TT) have revolutionised the outcomes for melanoma. Other than the approval of pembrolizumab for resected stage IIB/IIC in February 2023, there were no changes in the Systemic Anti-Cancer Therapy (SACT) treatments available for melanoma in England between 2019 and 2023. The national SACT dataset provides an insight on systemic treatment use during this timeframe. The purpose of this study was to evaluate the patterns of use and costs of SACT for melanoma between 2019 and 2023.

Materials and Methods

Data on prescriptions of SACT for adjuvant and metastatic disease between April 2019 to March 2023 were obtained from the SACT dataset and joinpoint regression analyses were used to look for any trends and change in trends. The list prices reported on the British National Formulary (BNF) were used to model drug acquisition costs.

Results

Data were available from a total of 71 Hospital Trusts. There was a non significant increasing trend in the adjuvant prescriptions (semestral percentage change = 3.25, 95% confidence interval [CI] -2.15–8.96, p = 0.22) and a non significant negative trend in the metastatic prescriptions (semestral percentage change = -0.59, 95% CI -3.02–1.92, p = 0.64) from April 2019 to March 2023. The estimated costs for SACT in the same timeframe were approximately £ 1.2 billion. Despite an increase in the spending on adjuvant therapy, the total costs in the financial year 2022–2023 decreased compared to 2019–2020 due to a slight reduction in the spending on metastatic treatment.

Conclusions

The opposite trends seen for adjuvant and metastatic prescriptions are a potential indicator of the impact of adjuvant treatment on development of distant metastases.

导言检查点抑制剂（CPI）和靶向治疗（TT）彻底改变了黑色素瘤的治疗效果。除了 2023 年 2 月批准将 pembrolizumab 用于切除的 IIB/IIC 期黑色素瘤治疗外，2019 年至 2023 年期间英格兰黑色素瘤的全身抗癌疗法（SACT）没有发生任何变化。全国 SACT 数据集可帮助我们深入了解这段时间内系统治疗的使用情况。本研究旨在评估2019年至2023年期间黑色素瘤SACT的使用模式和成本。材料与方法从SACT数据集中获取了2019年4月至2023年3月期间用于辅助治疗和转移性疾病的SACT处方数据，并使用连接点回归分析来寻找任何趋势和趋势变化。英国国家处方集（BNF）上报告的清单价格被用来模拟药物采购成本。从2019年4月到2023年3月，辅助治疗处方呈非显著增长趋势（半数百分比变化=3.25，95%置信区间[CI] -2.15-8.96，p=0.22），转移性处方呈非显著负增长趋势（半数百分比变化=-0.59，95%置信区间[CI] -3.02-1.92，p=0.64）。在同一时间段内，SACT 的估计成本约为 12 亿英镑。尽管辅助治疗的支出有所增加，但由于转移性治疗的支出略有减少，2022-2023 财年的总成本与 2019-2020 财年相比有所下降。结论辅助治疗和转移性处方的相反趋势是辅助治疗对远处转移发展影响的一个潜在指标。

{"title":"Patterns of systemic treatment for melanoma: An insight on trends and costs between 2019–2023 from the English systemic anti-cancer therapy national database","authors":"Tommaso Bosetti , Oliver John Kennedy , Rebecca Lee , Avinash Gupta , Patricio Serra , Nadia Ali , Avanti Andhale , Sophia Kreft , Paul Lorigan","doi":"10.1016/j.ejcskn.2024.100279","DOIUrl":"10.1016/j.ejcskn.2024.100279","url":null,"abstract":"<div><h3>Introduction</h3><div>Checkpoint inhibitors (CPI) and targeted therapy (TT) have revolutionised the outcomes for melanoma. Other than the approval of pembrolizumab for resected stage IIB/IIC in February 2023, there were no changes in the Systemic Anti-Cancer Therapy (SACT) treatments available for melanoma in England between 2019 and 2023. The national SACT dataset provides an insight on systemic treatment use during this timeframe. The purpose of this study was to evaluate the patterns of use and costs of SACT for melanoma between 2019 and 2023.</div></div><div><h3>Materials and Methods</h3><div>Data on prescriptions of SACT for adjuvant and metastatic disease between April 2019 to March 2023 were obtained from the SACT dataset and joinpoint regression analyses were used to look for any trends and change in trends. The list prices reported on the British National Formulary (BNF) were used to model drug acquisition costs.</div></div><div><h3>Results</h3><div>Data were available from a total of 71 Hospital Trusts. There was a non significant increasing trend in the adjuvant prescriptions (semestral percentage change = 3.25, 95% confidence interval [CI] -2.15–8.96, p = 0.22) and a non significant negative trend in the metastatic prescriptions (semestral percentage change = -0.59, 95% CI -3.02–1.92, p = 0.64) from April 2019 to March 2023. The estimated costs for SACT in the same timeframe were approximately £ 1.2 billion. Despite an increase in the spending on adjuvant therapy, the total costs in the financial year 2022–2023 decreased compared to 2019–2020 due to a slight reduction in the spending on metastatic treatment.</div></div><div><h3>Conclusions</h3><div>The opposite trends seen for adjuvant and metastatic prescriptions are a potential indicator of the impact of adjuvant treatment on development of distant metastases.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100279"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143183585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical characteristics and treatments of Merkel cell carcinoma in Japan: A multi-center retrospective study 日本梅克尔细胞癌的临床特点和治疗：一项多中心回顾性研究

EJC Skin Cancer

Pub Date : 2025-01-01 DOI: 10.1016/j.ejcskn.2025.100755

Eiji Nakano , Motoki Nakamura , Shuichi Ohe , Shusuke Kawashima , Ayano Maruyama , Wataru Omata , Takamichi Ito , Yuki Yamamoto , Akira Kaneko , Kenta Nakama , Teruki Yanagi , Takayuki Suyama , Susumu Fujiwara , Yasuhiro Nakamura , Taku Fujimura , Takeru Funakoshi , Junji Kato , Naohito Hatta , Shigeto Matsushita , Kohei Oashi , Kenjiro Namikawa

Background

Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous neuroendocrine carcinoma with limited data from Asian populations.

Material and methods

We retrospectively analyzed data from 216 patients with stage I–III MCC who received surgery or radiotherapy, and 76 patients at any stage who received systemic therapy, across 36 Japanese institutions between April 2018 and March 2022.

Results

The cohort demonstrated a higher incidence in females and a high rate of Merkel cell polyomavirus (MCPyV) positivity. Among stage I–III patients, 103 underwent surgery alone, 83 were treated with surgery and adjuvant radiotherapy, and 30 received radiotherapy alone. The 1-year recurrence-free survival (RFS) and overall survival (OS) rates were 73.7 % and 90.7 %, respectively. Although radiotherapy alone correlated with worse RFS and OS, no significant differences were observed among stage I–II patients treated with curative-intent surgery, surgery plus adjuvant radiotherapy, or radiotherapy alone. Among 76 patients with unresectable or metastatic MCC who received systemic therapy, 72 received first-line avelumab; with a 43.1 % response rate (RR), a median progression-free survival (PFS) of 9.9 months, and a median OS of 38.7 months. After avelumab failure, second-line chemotherapy yield a 46.2 % RR and a median PFS of 4.1 months.

Conclusion

Japanese patients with MCC exhibited distinct clinical characteristics compared to Western populations, with comparable avelumab effectiveness. Outcomes did not differ significantly across modalities in patients with localized disease treated with curative intent. This largest real-world Asian MCC dataset provides key insights for optimizing treatment strategies for Asian patients.

梅克尔细胞癌（MCC）是一种罕见的侵袭性皮肤神经内分泌癌，来自亚洲人群的资料有限。材料和方法我们回顾性分析了2018年4月至2022年3月期间来自日本36家机构的216名接受手术或放疗的I-III期MCC患者和76名接受全身治疗的任何阶段患者的数据。结果该队列显示女性发病率较高，且默克尔细胞多瘤病毒（MCPyV）阳性率较高。I-III期患者中，单纯手术103例，手术加辅助放疗83例，单纯放疗30例。1年无复发生存率（RFS）和总生存率（OS）分别为73.7 %和90.7 %。虽然单独放疗与更差的RFS和OS相关，但在治疗目的手术、手术加辅助放疗或单独放疗的I-II期患者中没有观察到显著差异。在76例接受全身治疗的不可切除或转移性MCC患者中，72例接受了一线avelumab治疗；缓解率（RR）为43.1% %，中位无进展生存期（PFS）为9.9个月，中位OS为38.7个月。在avelumab失败后，二线化疗的RR为46.2% %，中位PFS为4.1个月。结论：与西方人群相比，日本MCC患者表现出不同的临床特征，具有相当的avelumab有效性。在以治愈为目的的局部疾病患者中，不同治疗方式的结果没有显著差异。这个最大的真实世界亚洲MCC数据集为优化亚洲患者的治疗策略提供了关键见解。

{"title":"Clinical characteristics and treatments of Merkel cell carcinoma in Japan: A multi-center retrospective study","authors":"Eiji Nakano , Motoki Nakamura , Shuichi Ohe , Shusuke Kawashima , Ayano Maruyama , Wataru Omata , Takamichi Ito , Yuki Yamamoto , Akira Kaneko , Kenta Nakama , Teruki Yanagi , Takayuki Suyama , Susumu Fujiwara , Yasuhiro Nakamura , Taku Fujimura , Takeru Funakoshi , Junji Kato , Naohito Hatta , Shigeto Matsushita , Kohei Oashi , Kenjiro Namikawa","doi":"10.1016/j.ejcskn.2025.100755","DOIUrl":"10.1016/j.ejcskn.2025.100755","url":null,"abstract":"<div><h3>Background</h3><div>Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous neuroendocrine carcinoma with limited data from Asian populations.</div></div><div><h3>Material and methods</h3><div>We retrospectively analyzed data from 216 patients with stage I–III MCC who received surgery or radiotherapy, and 76 patients at any stage who received systemic therapy, across 36 Japanese institutions between April 2018 and March 2022.</div></div><div><h3>Results</h3><div>The cohort demonstrated a higher incidence in females and a high rate of Merkel cell polyomavirus (MCPyV) positivity. Among stage I–III patients, 103 underwent surgery alone, 83 were treated with surgery and adjuvant radiotherapy, and 30 received radiotherapy alone. The 1-year recurrence-free survival (RFS) and overall survival (OS) rates were 73.7 % and 90.7 %, respectively. Although radiotherapy alone correlated with worse RFS and OS, no significant differences were observed among stage I–II patients treated with curative-intent surgery, surgery plus adjuvant radiotherapy, or radiotherapy alone. Among 76 patients with unresectable or metastatic MCC who received systemic therapy, 72 received first-line avelumab; with a 43.1 % response rate (RR), a median progression-free survival (PFS) of 9.9 months, and a median OS of 38.7 months. After avelumab failure, second-line chemotherapy yield a 46.2 % RR and a median PFS of 4.1 months.</div></div><div><h3>Conclusion</h3><div>Japanese patients with MCC exhibited distinct clinical characteristics compared to Western populations, with comparable avelumab effectiveness. Outcomes did not differ significantly across modalities in patients with localized disease treated with curative intent. This largest real-world Asian MCC dataset provides key insights for optimizing treatment strategies for Asian patients.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100755"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145158041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term local recurrence and further primary skin cancers in cutaneous basal cell carcinoma with involved or close primary excision margins 长期局部复发和进一步原发性皮肤癌的皮肤基底细胞癌累及或接近原发切除边缘

EJC Skin Cancer

Pub Date : 2025-01-01 DOI: 10.1016/j.ejcskn.2025.100314

B. Clay , R. Manton , J. Kiely , A. Patel , A. Roshan

引用次数: 0

Evidence on the Use of Sonidegib as Neoadjuvant Therapy in real practice in Spain: A multicenter case series 索地吉在西班牙作为新辅助治疗的证据：一个多中心的病例系列

EJC Skin Cancer

Pub Date : 2025-01-01 DOI: 10.1016/j.ejcskn.2025.100315

E. Gallo-Gutierrez , C. Abril Pérez , R. Botella-Estrada , M. Mayor Arenal , L. Leal Canosa , A. Conde-Taboada , E. Masferrer i Niubò , P. Rodríguez-Jiménez

引用次数: 0

Cutaneous adverse events of pan-RAF inhibitor naporafenib (LXH254) containing drug combinations in NRAS-mutant metastatic melanoma 泛raf抑制剂naporafenib （LXH254）联合用药治疗nras突变转移性黑色素瘤的皮肤不良事件

EJC Skin Cancer

Pub Date : 2025-01-01 DOI: 10.1016/j.ejcskn.2025.100283

Sabine Hoheisel , Jacopo Roggero , Joanna Mangana , Reinhard Dummer , Lukas Kraehenbuehl , Egle Ramelyte

Introduction

Naporafenib (LXH254) is an orally bioavailable, type II RAF inhibitor that inhibits both BRAF and CRAF, thereby reducing paradoxical activation and inhibiting the mitogen-activated protein kinase (MAPK) signaling. A phase I and II study showed promising results in the treatment of neuroblastoma and NRAS-mutant melanoma. However, naporafenib-related skin toxicities such as rash and acneiform dermatitis appeared in 35 % and 28 % of treated patients, respectively. As acneiform eruptions can significantly affect patients’ quality of life and lead to dose-reduction or discontinuation, appropriate diagnostics, and management of cutaneous adverse events, including prophylactic and supportive measures, are essential.

Patients and methods

In order to deepen the knowledge regarding cutaneous side effects of RAF inhibitors we present a case-series of five patients treated with naporafenib for metastatic melanoma who developed drug-related papulo-pustular rash.

Results

Analyzing the individual skin-related toxicities, histopathological findings, the impact of skin toxicity on cancer treatment and the different management strategies, our findings indicate that intensive prophylactic measures and early detection are as crucial as specific diagnostics for a rapid control of skin toxicity associated with naporafenib.

Conclusion

Additional preemptive measures as systemic doxycycline, tapered after the first weeks may be one possible approach to impede dose reduction or interruption of naporafenib.

naporafenib （LXH254）是一种口服生物可利用的II型RAF抑制剂，可抑制BRAF和CRAF，从而减少矛盾激活并抑制丝裂原活化蛋白激酶（MAPK）信号传导。一项I期和II期研究显示，在治疗神经母细胞瘤和nras突变黑色素瘤方面有希望的结果。然而，纳波拉非尼相关的皮肤毒性，如皮疹和痤疮样皮炎分别出现在35% %和28% %的治疗患者中。由于痤疮疹可显著影响患者的生活质量并导致剂量减少或停药，因此适当的诊断和处理皮肤不良事件，包括预防性和支持性措施是至关重要的。患者和方法为了加深对RAF抑制剂皮肤副作用的了解，我们提出了5例接受纳波非尼治疗的转移性黑色素瘤患者的病例系列，这些患者出现了药物相关的丘疹-脓疱疹。结果分析个体皮肤相关毒性、组织病理学结果、皮肤毒性对癌症治疗的影响以及不同的管理策略，我们的研究结果表明，强化预防措施和早期发现对于快速控制那波非尼相关皮肤毒性至关重要。结论预防性用药如1周后逐渐停用强力霉素可能是阻止纳波非尼减量或中断用药的一种可能方法。

{"title":"Cutaneous adverse events of pan-RAF inhibitor naporafenib (LXH254) containing drug combinations in NRAS-mutant metastatic melanoma","authors":"Sabine Hoheisel , Jacopo Roggero , Joanna Mangana , Reinhard Dummer , Lukas Kraehenbuehl , Egle Ramelyte","doi":"10.1016/j.ejcskn.2025.100283","DOIUrl":"10.1016/j.ejcskn.2025.100283","url":null,"abstract":"<div><h3>Introduction</h3><div>Naporafenib (LXH254) is an orally bioavailable, type II RAF inhibitor that inhibits both BRAF and CRAF, thereby reducing paradoxical activation and inhibiting the mitogen-activated protein kinase (MAPK) signaling. A phase I and II study showed promising results in the treatment of neuroblastoma and NRAS-mutant melanoma. However, naporafenib-related skin toxicities such as rash and acneiform dermatitis appeared in 35 % and 28 % of treated patients, respectively. As acneiform eruptions can significantly affect patients’ quality of life and lead to dose-reduction or discontinuation, appropriate diagnostics, and management of cutaneous adverse events, including prophylactic and supportive measures, are essential.</div></div><div><h3>Patients and methods</h3><div>In order to deepen the knowledge regarding cutaneous side effects of RAF inhibitors we present a case-series of five patients treated with naporafenib for metastatic melanoma who developed drug-related papulo-pustular rash.</div></div><div><h3>Results</h3><div>Analyzing the individual skin-related toxicities, histopathological findings, the impact of skin toxicity on cancer treatment and the different management strategies, our findings indicate that intensive prophylactic measures and early detection are as crucial as specific diagnostics for a rapid control of skin toxicity associated with naporafenib.</div></div><div><h3>Conclusion</h3><div>Additional preemptive measures as systemic doxycycline, tapered after the first weeks may be one possible approach to impede dose reduction or interruption of naporafenib.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100283"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143509225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

EJC Skin Cancer

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀